U.S. Cancer Biopsy Market Analysis, Growth Opportunities and Forecast to 2028

U.S. Cancer Biopsy Industry Overview

The U.S. cancer biopsy market size is expected to reach USD 15.98 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 11.0% from 2021 to 2028. The increasing usage of technologically advanced devices for the early detection of diseases is one of the key factors driving the market.

U.S. cancer biopsy market size, by type, 2017 - 2028 (USD Billion)

U.S. Cancer Biopsy Market Segmentation

Grand View Research has segmented the U.S. cancer biopsy market on the basis of type, application, and site (organ):

Based on the Type Insights, the market is segmented into Fine-needle Aspiration, Core Biopsy, Surgical Biopsy, Skin Biopsy /Punch Biopsy and Others.

  • The fine-needle aspiration biopsy (FNA) dominated the market in 2020 with a revenue share of more than 30.0%. This can be attributed to the fact that it is a simple and comparatively noninvasive approach that demands a skilled aspirator, coupled with the use of needles, stains, and syringes This has prompted several companies to invest in the development of FNAB systems.
  • Core needle procedures have gained significant traction over the past few years across breast biopsy applications. This shift from FNA to CNB is ongoing, especially among consumers in the U.S. The core needle biopsy, coupled with ultrasound guidance, has considerable potential to become the standard approach for amenable lesions. This is expected to promote the use of core needle biopsy in oncology indication diagnosis.
  • A surgical biopsy is a traditional approach for biopsies in patients suffering from cancer; in contrast to the needle biopsy. Incisional biopsies are most commonly adopted when needle biopsies fail to offer conclusive results, or the suspicious area is larger for sampling. This has contributed to the demand and revenue generated by surgical biopsies in oncology indication diagnosis.

Based on the Application Insights, the market is segmented into Screening & Monitoring, Diagnostics, Investigational & Translational Research, Pharma & Biopharma Discovery & Development.

  • The screening and monitoring application segment accounted for the largest revenue share of over 50.0% in 2020. Active participation of national research authorities has driven the adoption of different biopsy techniques in screening and monitoring applications.
  • The American Cancer Society (ACS) offers an annual report for healthcare professionals that summarizes present cancer screening guidelines, which are inclusive of present recommendations as well as updated recommendations. Biopsy has gained immense attention among professionals for early detection of cancer, particularly when it is difficult to make a direct screening recommendation.

Based on the Site (Organ) Insights, the market is segmented into Liver, Breast, Thyroid, Prostate Gland, Uterus & Cervix, Kidney, Bladder, Lungs, Pancreas, and Others.

  • The breast segment accounted for the largest revenue share of 20.0% in 2020. The rising number of patients suspected to suffer from breast cancer has led to the increasing demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis. Image-guided needle biopsy has emerged as an accurate and safe nonsurgical approach for the detection of suspicious tissues in breast imaging.
  • Presently, biopsy has become a preferable approach to diagnose lung cancer. Various tools have been developed for lung tissue biopsy that is employed for the staging of lung cancer. Biopsy has emerged as a preferred choice of diagnostic tool attributed to its accuracy in lesion localization.

Key Companies Profile & Market Share Insights

The U.S. market for cancer biopsy is expected to witness tremendous growth in the near future. The increasing number of technological collaborations between operating entities, coupled with the expanding product portfolio of operating players, has intensified the market competition.   

Some of the prominent players operating in the U.S. cancer biopsy market include,

  • Becton, Dickinson and Company
  • IZI Medical Products
  • Johnson & Johnson
  • Argon Medical
  • Cook Medical
  • Spectra Medical Devices, Inc.
  • Medtronic plc.
  • Boston Scientific Corporation
  • Conmed Corporation
  • INRAD, Inc.

Order a free sample PDF of the U.S. Cancer Biopsy Market Intelligence Study, published by Grand View Research.

Comments are closed